Avenue du Pré-Aily 14

4031 Liège Angleur



Foundation date



#Biotechnology - Therapeutics


Therapeutic areas

Imcyse develops active targeted immune therapies (ImotopesÔ) that locally inhibit the immune cells involved in the destruction of the diseased organ. The targeted approach and memory effect of the Imcyse technology help to prevent and cure diseases with no current therapeutic alternative, caused by disruptions of the immune system without impairing the patient’s immune defences. 

Upcoming events

Latest news

  • Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

    Thursday November 30th 2023

  • Agomab appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

    Wednesday November 29th 2023

  • Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure

    Wednesday November 29th 2023